Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour - Concepedia

Concepedia

Publication | Open Access

Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour

DOI Full Paper Access

30

Citations

18

References

2016

Year

Andrew J. Wagner, Mark Agulnik, Michael C. Heinrich, Daruka Mahadevan, Richard F. Riedel, Margaret von Mehren, Jonathan C. Trent, George D. Demetri, Christopher L. Corless, Murray Yule,

European Journal of Cancer

Abstract

The combination of onalespib plus imatinib was well tolerated but exhibited limited antitumour activity as dosed in this TKI-resistant GIST patient population. Trial registration ID: clinicaltrials.gov: NCT01294202.

References

	Year	Citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors George D. Demetri, Margaret von Mehren, Charles D. Blanke, New England Journal of Medicine	2002	4.4K
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor Michael C. Heinrich, Christopher L. Corless, George D. Demetri, Journal of Clinical Oncology	2003	2.3K
A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors Lei L. Chen, Jonathan C. Trent, Elsie F. Wu, Cancer Research	2004	341
Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial Christopher L. Corless, Karla V. Ballman, Cristina R. Antonescu, Journal of Clinical Oncology	2014	312
Heat Shock Protein 90 Inhibition in Imatinib-Resistant Gastrointestinal Stromal Tumor Sebastian Bauer, Lynn K. Yu, George D. Demetri, Cancer Research	2006	264
Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design Andrew Woodhead, Hayley C. Angove, Maria G. Carr, Journal of Medicinal Chemistry Pharmaceutical ScienceNovel InhibitorDrug TargetHit IdentificationBiomolecular Structure Prediction	2010	258
Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors Ann W. Gramza, Christopher L. Corless, Michael C. Heinrich Clinical Cancer Research	2009	223
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial Yoon‐Koo Kang, Min‐Hee Ryu, Changhoon Yoo, The Lancet Oncology Gastrointestinal OncologyMedicinePathologyMolecular OncologyCancer Treatment	2013	184
17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells Gerard Fumo, Cem Akin, Dean D. Metcalfe, Blood	2003	143

Page 1